Cargando…

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination

We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples were collected two months after vaccination f...

Descripción completa

Detalles Bibliográficos
Autores principales: Barocci, Simone, Orlandi, Chiara, Diotallevi, Aurora, Buffi, Gloria, Ceccarelli, Marcello, Vandini, Daniela, Carlotti, Eugenio, Galluzzi, Luca, Rocchi, Marco Bruno Luigi, Magnani, Mauro, Casabianca, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031424/
https://www.ncbi.nlm.nih.gov/pubmed/35455240
http://dx.doi.org/10.3390/vaccines10040491
_version_ 1784692386304098304
author Barocci, Simone
Orlandi, Chiara
Diotallevi, Aurora
Buffi, Gloria
Ceccarelli, Marcello
Vandini, Daniela
Carlotti, Eugenio
Galluzzi, Luca
Rocchi, Marco Bruno Luigi
Magnani, Mauro
Casabianca, Anna
author_facet Barocci, Simone
Orlandi, Chiara
Diotallevi, Aurora
Buffi, Gloria
Ceccarelli, Marcello
Vandini, Daniela
Carlotti, Eugenio
Galluzzi, Luca
Rocchi, Marco Bruno Luigi
Magnani, Mauro
Casabianca, Anna
author_sort Barocci, Simone
collection PubMed
description We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples were collected two months after vaccination from a total of 1248 subjects. The results showed that the heterologous vaccine schedule induced a significantly higher humoral response followed by homologous BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S vaccines (p < 0.0001). Moreover, analyzing factors (i.e., vaccine schedule, sex, age, BMI, smoking, diabetes, cardiovascular diseases, respiratory tract diseases, COVID-19 diagnosis, vaccine side effects) influencing the IgG anti-S response, we found that only the type of vaccine affected the antibody titer (p < 0.0001). Only mild vaccine reactions resolved within few days (40% of subjects) and no severe side effects for either homologous groups or the heterologous group were reported. Our data support the use of heterologous vaccination as an effective and safe alternative to increase humoral immunity against COVID-19.
format Online
Article
Text
id pubmed-9031424
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90314242022-04-23 Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination Barocci, Simone Orlandi, Chiara Diotallevi, Aurora Buffi, Gloria Ceccarelli, Marcello Vandini, Daniela Carlotti, Eugenio Galluzzi, Luca Rocchi, Marco Bruno Luigi Magnani, Mauro Casabianca, Anna Vaccines (Basel) Brief Report We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples were collected two months after vaccination from a total of 1248 subjects. The results showed that the heterologous vaccine schedule induced a significantly higher humoral response followed by homologous BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S vaccines (p < 0.0001). Moreover, analyzing factors (i.e., vaccine schedule, sex, age, BMI, smoking, diabetes, cardiovascular diseases, respiratory tract diseases, COVID-19 diagnosis, vaccine side effects) influencing the IgG anti-S response, we found that only the type of vaccine affected the antibody titer (p < 0.0001). Only mild vaccine reactions resolved within few days (40% of subjects) and no severe side effects for either homologous groups or the heterologous group were reported. Our data support the use of heterologous vaccination as an effective and safe alternative to increase humoral immunity against COVID-19. MDPI 2022-03-23 /pmc/articles/PMC9031424/ /pubmed/35455240 http://dx.doi.org/10.3390/vaccines10040491 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Barocci, Simone
Orlandi, Chiara
Diotallevi, Aurora
Buffi, Gloria
Ceccarelli, Marcello
Vandini, Daniela
Carlotti, Eugenio
Galluzzi, Luca
Rocchi, Marco Bruno Luigi
Magnani, Mauro
Casabianca, Anna
Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
title Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
title_full Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
title_fullStr Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
title_full_unstemmed Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
title_short Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
title_sort evaluation of two-month antibody levels after heterologous chadox1-s/bnt162b2 vaccination compared to homologous chadox1-s or bnt162b2 vaccination
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031424/
https://www.ncbi.nlm.nih.gov/pubmed/35455240
http://dx.doi.org/10.3390/vaccines10040491
work_keys_str_mv AT baroccisimone evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination
AT orlandichiara evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination
AT diotalleviaurora evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination
AT buffigloria evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination
AT ceccarellimarcello evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination
AT vandinidaniela evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination
AT carlottieugenio evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination
AT galluzziluca evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination
AT rocchimarcobrunoluigi evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination
AT magnanimauro evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination
AT casabiancaanna evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination